FDA
- Status: approved
increased dosing interval of biological therapy (increased dosing interval of biological therapy) regulatory status in United States.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA has authorised it.
Rigshospitalet, Denmark is the originator. The local marketing authorisation holder may differ — check the official source linked above.